Drug Interactions between C1 esterase inhibitor (human) and Oreton Methyl
This report displays the potential drug interactions for the following 2 drugs:
- C1 esterase inhibitor (human)
- Oreton Methyl (methyltestosterone)
Interactions between your drugs
methylTESTOSTERone C1 esterase inhibitor, human
Applies to: Oreton Methyl (methyltestosterone) and C1 esterase inhibitor (human)
MONITOR: Thromboembolism may occur during treatment with C1 esterase inhibitors, and concurrent use of other agents that are also associated with this adverse effect can potentiate the risk. Serious arterial and venous thromboembolic events, including myocardial infarction, deep vein thrombosis, pulmonary embolism, transient ischemic attack and stroke, have been reported with the use of plasma-derived C1 esterase inhibitor products at recommended dosages in patients with risk factors. A definitive causal relationship has not been established. Risk factors may include the presence of an indwelling venous catheter/access device, prior history of thrombosis, underlying atherosclerosis, morbid obesity, immobility, and concomitant use of medications such as oral contraceptives or certain androgens. Data from in vitro and in vivo animal thrombogenicity studies conducted with a plasma-derived C1 esterase inhibitor showed a potential for clot formation when administered at dosages 14 times the recommended clinical dose. Thrombotic events have been reported with another C1 esterase inhibitor product when used off-label at high dosages in newborns and young children with congenital heart anomalies during or after cardiac surgery.
MANAGEMENT: Caution is advised when C1 esterase inhibitors are used with other drugs that have thrombogenic effects such as androgens, estrogens, erythropoiesis- or thrombopoiesis-stimulating agents, or selective estrogen receptor modulators. Close monitoring for thromboembolic events is recommended during and after administration of C1 esterase inhibitors. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain; shortness of breath; rapid pulse; pain, swelling, and/or discoloration in an arm or leg; and numbness or weakness on one side of the body.
References
- (2022) "Product Information. Cinryze (C1 esterase inhibitor, human)." ViroPharma Incorporated
- (2022) "Product Information. Berinert (C1 esterase inhibitor, human)." CSL Behring LLC
- Gandhi PK, Gentry WM, Bottorff MB (2012) "Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database." Pharmacotherapy, 32, p. 902-9
- (2015) "Product Information. Ruconest (conestat alfa)." Valeant Pharmaceuticals
Drug and food interactions
No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.